CN113474007A - 缀合物 - Google Patents
缀合物 Download PDFInfo
- Publication number
- CN113474007A CN113474007A CN201980092600.6A CN201980092600A CN113474007A CN 113474007 A CN113474007 A CN 113474007A CN 201980092600 A CN201980092600 A CN 201980092600A CN 113474007 A CN113474007 A CN 113474007A
- Authority
- CN
- China
- Prior art keywords
- conjugate
- alkyl
- group
- hydrogen
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0045—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1820626.8 | 2018-12-18 | ||
| GBGB1820626.8A GB201820626D0 (en) | 2018-12-18 | 2018-12-18 | Conjugates |
| PCT/EP2019/086120 WO2020127602A1 (en) | 2018-12-18 | 2019-12-18 | Conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113474007A true CN113474007A (zh) | 2021-10-01 |
Family
ID=65147114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980092600.6A Pending CN113474007A (zh) | 2018-12-18 | 2019-12-18 | 缀合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220054658A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3897737A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022514335A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210106496A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113474007A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019400788A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021011860A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3123960A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB201820626D0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021006802A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020127602A1 (cg-RX-API-DMAC7.html) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114685430A (zh) * | 2022-03-18 | 2022-07-01 | 浙江大学 | 芬苯达唑类似物及制备方法和应用 |
| CN120987848A (zh) * | 2025-07-10 | 2025-11-21 | 广州大学 | 一种含胍基结构单元的ε-己内酰胺化合物及其制备方法和应用 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024049306A1 (en) * | 2022-08-31 | 2024-03-07 | Lopez Gonzalez Ricardo | Chemical conjugates, compositions, and methods of preparation and use thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102395565A (zh) * | 2008-12-05 | 2012-03-28 | 俄勒冈健康科学大学 | 具有抗寄生物活性和抗感染活性的化合物 |
| CN103261169A (zh) * | 2010-09-24 | 2013-08-21 | 密歇根大学董事会 | 脱泛素酶抑制剂及其应用方法 |
| US20130345270A1 (en) * | 2010-11-12 | 2013-12-26 | Waake Forest University Health Sciences | Methods of treating cancer and other disorders |
| US20140038914A1 (en) * | 2011-01-18 | 2014-02-06 | The Royal Institution For The Advancement Of Learning/Mcgill University | Compounds for use in the treatment of bacterial infection |
| CN107257793A (zh) * | 2015-01-20 | 2017-10-17 | 梅里亚股份有限公司 | 抗蠕虫化合物、组合物及其使用方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0068485B1 (en) | 1981-07-01 | 1987-11-11 | Sanraku Incorporated | Novel antibiotics and process for production thereof |
| US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| WO2019060634A1 (en) | 2017-09-20 | 2019-03-28 | Thiogenesis Therapeutics, Inc. | METHODS OF TREATING CYSTEAMINE SENSITIVE DISORDERS |
-
2018
- 2018-12-18 GB GBGB1820626.8A patent/GB201820626D0/en not_active Ceased
-
2019
- 2019-12-18 KR KR1020217022384A patent/KR20210106496A/ko not_active Ceased
- 2019-12-18 AU AU2019400788A patent/AU2019400788A1/en not_active Abandoned
- 2019-12-18 US US17/416,284 patent/US20220054658A1/en not_active Abandoned
- 2019-12-18 WO PCT/EP2019/086120 patent/WO2020127602A1/en not_active Ceased
- 2019-12-18 BR BR112021011860-8A patent/BR112021011860A2/pt unknown
- 2019-12-18 CA CA3123960A patent/CA3123960A1/en active Pending
- 2019-12-18 EP EP19829152.8A patent/EP3897737A1/en not_active Withdrawn
- 2019-12-18 JP JP2021535300A patent/JP2022514335A/ja active Pending
- 2019-12-18 CN CN201980092600.6A patent/CN113474007A/zh active Pending
- 2019-12-18 MX MX2021006802A patent/MX2021006802A/es unknown
-
2025
- 2025-01-17 JP JP2025007027A patent/JP2025072404A/ja active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102395565A (zh) * | 2008-12-05 | 2012-03-28 | 俄勒冈健康科学大学 | 具有抗寄生物活性和抗感染活性的化合物 |
| CN103261169A (zh) * | 2010-09-24 | 2013-08-21 | 密歇根大学董事会 | 脱泛素酶抑制剂及其应用方法 |
| US20130345270A1 (en) * | 2010-11-12 | 2013-12-26 | Waake Forest University Health Sciences | Methods of treating cancer and other disorders |
| US20140038914A1 (en) * | 2011-01-18 | 2014-02-06 | The Royal Institution For The Advancement Of Learning/Mcgill University | Compounds for use in the treatment of bacterial infection |
| CN107257793A (zh) * | 2015-01-20 | 2017-10-17 | 梅里亚股份有限公司 | 抗蠕虫化合物、组合物及其使用方法 |
Non-Patent Citations (6)
| Title |
|---|
| ALAN L. SEWELL等: "Fast and Flexible Synthesis of Pantothenic Acid and CJ-15, 801", ORGANIC LETTERS, vol. 13, no. 4, 20 January 2011 (2011-01-20), pages 800 - 803, XP055052154, DOI: 10.1021/ol103114w * |
| CHONG HAN, RUICHAO SHEN, SHUN SU, AND JOHN A. PORCO: "Copper-Mediated Synthesis of N-Acyl Vinylogous Carbamic Acids and Derivatives: Synthesis of the Antibiotic CJ-15, 8011-61", ORGANIC LETTERS, vol. 6, no. 1, 11 December 2003 (2003-12-11), pages 27 - 30, XP055052152, DOI: 10.1021/ol0360041 * |
| CHRISTINA SPRY等: "Structure-activity analysis of CJ-15, 801 analogues that interact with Plasmodium falciparum pantothenate kinase and inhibit parasite proliferation", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 143, 1 January 2018 (2018-01-01), pages 1139 - 1147 * |
| LINDY HOLDEN-DYE, ROBERT J WALKER: "Anthelmintic drugs and nematicides: studies in Caenorhabditis elegans", WORMBOOK, 16 December 2014 (2014-12-16), pages 1 - 29, XP055478099, DOI: 10.1895/wormbook.1.143.2 * |
| 宋军科;才学鹏;骆学农;林青;窦永喜;于三科;: "寄生虫半胱氨酸蛋白酶研究进展", 动物医学进展, no. 12, 20 December 2011 (2011-12-20) * |
| 邱宗文: "寄生虫的半胱氨酸蛋白酶", 国外医学.寄生虫病分册, no. 4, 15 August 2003 (2003-08-15) * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114685430A (zh) * | 2022-03-18 | 2022-07-01 | 浙江大学 | 芬苯达唑类似物及制备方法和应用 |
| CN120987848A (zh) * | 2025-07-10 | 2025-11-21 | 广州大学 | 一种含胍基结构单元的ε-己内酰胺化合物及其制备方法和应用 |
| CN120987848B (zh) * | 2025-07-10 | 2026-07-21 | 广州大学 | 一种含胍基结构单元的ε-己内酰胺化合物及其制备方法和应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| GB201820626D0 (en) | 2019-01-30 |
| KR20210106496A (ko) | 2021-08-30 |
| JP2025072404A (ja) | 2025-05-09 |
| JP2022514335A (ja) | 2022-02-10 |
| US20220054658A1 (en) | 2022-02-24 |
| WO2020127602A1 (en) | 2020-06-25 |
| EP3897737A1 (en) | 2021-10-27 |
| CA3123960A1 (en) | 2020-06-25 |
| MX2021006802A (es) | 2021-08-16 |
| AU2019400788A1 (en) | 2021-08-12 |
| BR112021011860A2 (pt) | 2021-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025072404A (ja) | コンジュゲート | |
| JP6419990B2 (ja) | ブロモドメイン阻害剤としてのベンゾイミダゾール誘導体 | |
| JPH10508613A (ja) | 内部寄生虫を駆除するためのジオキソモルホリンの使用、新規ジオキソモルホリンおよびそれらの製造方法 | |
| WO1982001873A1 (en) | 1-sulfo-2-oxoazetidine derivatives and process for their preparation | |
| TW201402537A (zh) | 犬尿胺酸-3-單氧化酶抑制劑,其醫藥組成物及使用方法 | |
| CH647757A5 (fr) | Derives de l'acide 3-aminopropanesulfonique ayant une activite membranaire renforcee. | |
| TW202342492A (zh) | 用於治療癌症之基於硫鏈絲菌肽之化合物及其製備 | |
| EA013244B1 (ru) | 8-МЕТОКСИ-9Н-ИЗОТИАЗОЛО[5,4-b]ХИНОЛИН-3,4-ДИОНЫ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ПРОТИВОИНФЕКЦИОННЫХ СРЕДСТВ | |
| CN108137599B (zh) | 化合物 | |
| JP7696301B2 (ja) | タンパク質分解のための化合物、組成物、および方法 | |
| JP2025524721A (ja) | メタロトーシス関連障害の処置において使用するためのセロトニン類似体 | |
| KR20240145010A (ko) | Klf2 유도제 및 이의 사용 방법 | |
| TW202525320A (zh) | 用於處置或預防中樞神經系損傷疾病的環狀胜肽衍生物組成物 | |
| EP2417151B1 (fr) | Peptides cycliques à activité antiparasitaire | |
| CN1257072A (zh) | 新的1,2-二硫戊环化合物、其制备方法及包含它们的药物组合物 | |
| US20050203180A1 (en) | Cinnamic acid dimers, their preparation and the use thereof for treating neurodegenerative disease | |
| BE1007544A3 (fr) | Derives de thioalkylthiocarbacephalosporines. | |
| US8058468B2 (en) | Carbamate antibiotics | |
| OA13294A (fr) | Molécules duales contenant un dérivé peroxydique, leur synthèse et leurs applications thérapeutiques. | |
| US20200079750A1 (en) | Compound or salt thereof, antiviral agent, and pharmaceutical composition | |
| Karmakar et al. | Evaluating the leishmanicidal activity of m-Nitrocinnamic acid containing lipophilic peptide against leishmania donovani | |
| WO2012116577A1 (zh) | 绿原酸类似物及其制备方法和应用 | |
| US20080280964A1 (en) | Novel Antibiotics Comprising Bis(1-Aryl-5-Tetrazolyl)Methane Derivatives | |
| NL8101439A (nl) | Aminozuurverbindingen en bereiding en hun gebruik als farmaceutisch preparaat. | |
| HK40111688A (en) | Inducers of klf2 and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20211001 |